Trial Profile
A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Enzalutamide; Fulvestrant
- Indications Advanced breast cancer; Male breast cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- 04 May 2023 Status changed from active, no longer recruiting to completed.
- 05 Jul 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 05 Jul 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.